|

Cancer Clinical Trials in Vermont

102 recruiting studies across 4 cities

All Trials in Vermont

Phase
Trial Phase Location
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPhase 3Berlin Corners
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Berlin Corners
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Berlin Corners
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Berlin Corners
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Berlin Corners
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Berlin Corners
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerPhase 2/3Berlin Corners
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Berlin Corners
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaPhase 3Berlin Corners
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Berlin Corners
Family Communications After Genetic TestingN/ABerlin Corners
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Berlin Corners
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Berlin Corners
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal CancerPhase 3Berlin Corners
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Berlin Corners
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Berlin Corners
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3Berlin Corners
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPhase 3Berlin Corners
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPhase 3Berlin Corners
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Berlin Corners
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialPhase 2Berlin Corners
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPhase 3Berlin Corners
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialPhase 2Berlin Corners
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Berlin Corners
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Berlin Corners
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Berlin Corners
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2Burlington
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Burlington
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Phase 3Burlington
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Burlington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Burlington
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 2Burlington
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)Phase 2Burlington
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPhase 3Burlington
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Burlington
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Burlington
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Burlington
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Burlington
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Burlington
Accelerated Pulmonary Rehabilitation in the Preoperative PeriodN/ABurlington
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPERPhase 2Burlington
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic TrialPhase 2Burlington
Care Coordination Educational Intervention Study for Patients From Rural Areas With Early Stage CancerN/ABurlington
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2Burlington
DOAC - Dosing Options in AntiCoagulation ProphylaxisPhase 3Burlington
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Burlington
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Burlington
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment—Burlington
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Phase 3Burlington
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3Phase 1Burlington
Fezolinetant for Treating Hot Flashes in Men With Prostate CancerPhase 2Burlington
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPECPhase 2Burlington
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens—Burlington
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II TrialPhase 2Burlington
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Burlington
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Burlington
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaPhase 3Burlington
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Burlington
MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin CancerPhase 2Burlington
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Burlington
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaN/ABurlington
Multi-disciplinary Care for Brain MetastasesN/ABurlington
Nutritional Prehabilitation to Improve Cancer Outcomes (N-PICO)N/ABurlington
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Burlington
Project: Every Child for Younger Patients With Cancer—Burlington
PumaRx Registry Trial—Burlington
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)—Burlington
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1Burlington
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3Burlington
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaPhase 1Burlington
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3Burlington
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Burlington
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPhase 3Burlington
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPhase 2Burlington
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2Burlington
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Burlington
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaPhase 2Burlington
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Burlington
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Burlington
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Burlington
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2Burlington
Venous Thromboembolism Prevention in Outpatients With GliomaPhase 2Burlington
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPhase 2Saint Johnsbury
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Saint Johnsbury
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyPhase 2Saint Johnsbury
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Saint Johnsbury
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialPhase 2Saint Johnsbury
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialPhase 3Saint Johnsbury
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePhase 3Saint Johnsbury
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal CancerPhase 3Saint Johnsbury
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersPhase 2Saint Johnsbury
Reaching Rural Cancer Survivors Who Smoke Using Text-Based ProgramPhase 3Saint Johnsbury
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasesPhase 3Saint Johnsbury
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Saint Johnsbury
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Saint Johnsbury
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 3Saint Johnsbury
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2Saint Johnsbury
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Saint Johnsbury
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerPhase 2Saint Johnsbury
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersPhase 2Saint Johnsbury
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2Saint Johnsbury
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer SurveillancePhase 2White River Junction

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.